Reported 4 days ago
Protagonist Therapeutics, Inc. (NASDAQ:PTGX), a biotechnology company, saw its stock rise significantly following a positive outcome from a phase 2 trial for its drug icotrokinra, which treats ulcerative colitis. In the first quarter of 2025, PTGX reported a 2.86% one-month return and a notable 50.15% increase over the last year, closing at $45.66 per share with a market capitalization of $2.83 billion. Despite its promising developments, it was noted that AI stocks may offer more attractive investment opportunities.
Source: YAHOO